The GC1F Gene: The Hidden Genetic Reason Black People Are More Vitamin D Deficient in the UK
By Bamidele Abudu, GPhC-Registered Pharmacist | Morlongevity
There is a gene variant carried by most people of African descent that profoundly shapes how their bodies process vitamin D.
It affects how vitamin D is transported around the body, how much of it is available to your cells, and, in a finding that genuinely surprised the scientific community, it may even influence your risk of developing cancer.
Yet it is rarely mentioned in a GP consultation.
As a pharmacist, I believe Black communities in Britain deserve access to this information, clearly explained, without jargon. So here it is.
First, a Quick Bit of Biology
When vitamin D enters your body, whether from sunlight, food, or a supplement, it cannot simply travel through your bloodstream on its own. It needs to be carried. There is a dedicated transport protein in your blood whose sole job is to pick up vitamin D and shuttle it to the liver and kidneys, where it is converted into the active form your body can use.
The gene that produces this transport protein is called the GC gene. And like most genes, it comes in several variants. Which variant you carry depends largely on your ancestry.
The three main variants are GC1F, GC1S, and GC2. GC1F is the ancestral form, the version that evolved in equatorial Africa, where UV exposure was abundant year-round. It is carried by roughly 86% of people with West African ancestry.
In people of European ancestry, the predominant variant is GC1S, and GC1F is found in only around 6% of that population.
This is not a minor genetic footnote. It is one of the most significant population differences in vitamin D biology known to science.
Why GC1F Creates Problems in the UK
GC1F evolved in an environment with abundant sunlight. In that context, it worked perfectly. The problem is that it was not built for life at 51 degrees north, where meaningful sunlight is only available for a few months a year.
On top of that, melanin, the pigment that gives darker skin its colour, acts as a natural UV filter. This is brilliant in high-sun environments where protecting the skin from UV damage matters.
But in the UK, where UV levels are already low and seasonal, it further reduces the skin’s ability to produce vitamin D from sunlight. Someone with deeply pigmented skin needs up to ten times more sun exposure to produce the same amount of vitamin D as someone with very light skin under identical conditions.
The result is predictable. UK data from one of the largest health studies ever conducted in this country found that among Black British adults, over a third were vitamin D deficient, 41% had insufficient levels, and only 16% had adequate levels. The average reading was well below the clinical adequacy threshold.
And then there is the guidance on supplementation. The current NHS recommendation is 400 IU of vitamin D per day for all adults, the same figure regardless of skin tone, genetics, or where you live.
Research presented to the government’s own nutrition advisory committee found that darker-skinned people in northern latitudes need roughly 720 IU per day just to avoid deficiency, and that correcting an existing deficiency typically requires 2,000 to 4,000 IU daily. One of the scientists on that committee explicitly warned that a one-size-fits-all approach would worsen health inequalities. The guidance has not been updated.
What Sustained Deficiency Actually Does to Your Health
This is not just about numbers on a blood test. Sustained vitamin D deficiency has measurable consequences:
- Heart and cardiovascular health: Research has found that a meaningful proportion of the difference in cardiovascular disease rates between Black and White populations is associated with lower vitamin D levels.
Low vitamin D has been linked to higher rates of high blood pressure, stroke, and cardiovascular mortality.
- Immune function: Vitamin D is a critical regulator of the immune system. It helps produce the body’s natural chemical defences against infection and supports the T cells that coordinate immune responses.
The disproportionate impact of COVID-19 on Black communities was accompanied by research linking vitamin D deficiency and the GC1F variant to increased susceptibility.
- Bone health: The relationship here is complex. Black populations generally have higher bone density than White populations, which has led some to suggest vitamin D deficiency is less relevant for this group.
But at severe levels of deficiency, bone health remains compromised, and other health risks persist.
- Cancer risk: Vitamin D plays a role in regulating cell growth and preventing the kind of uncontrolled multiplication that leads to tumours. Multiple large studies have found associations between low vitamin D and increased risk of bowel, breast, and prostate cancers.
The Surprising Finding: GC1F May Actually Protect Against Cancer
Here is where the story takes an unexpected turn, and it is genuinely important.
A large study that followed over 11,000 genotyped adults for up to 19 years found that people carrying two copies of the GC1F variant had a 23 to 26% lower risk of developing cancer compared to people with other variants.
A separate analysis of a large cancer screening trial also found significantly lower melanoma risk among GC1F carriers.
The striking detail: this cancer protection was not explained by vitamin D levels. Something else about the GC1F variant itself appeared to be conferring protection.
The most credible explanation involves the immune system. The GC1F transport protein has a particular structural feature that allows the immune system to convert it into a powerful immune activator. This activating compound, when produced, switches on macrophages,the immune system’s clean-up crew cells, which patrol the body destroying tumour cells, pathogens, and damaged cells.
Crucially, GC1F has the highest capacity of all three variants to undergo this conversion. The other two variants are less effective at it, and one cannot do it at all.
In other words, the GC1F variant that evolved in Africa, the one carried by the majority of people of African descent, appears to come with a built-in immune advantage that may meaningfully reduce cancer risk.
The Uncomfortable Tension
So here is where things sit. GC1F carriers may have a genuine genetic advantage for immune function and cancer protection. But they are also more likely to be chronically vitamin D deficient in the UK, receiving public health guidance that was never calibrated for their genetic background.
The biological advantage GC1F confers may be partially undermined by a public health failure to ensure adequate vitamin D levels in the population most likely to carry it. The government’s nutrition committee has been aware of the inadequacy of the 400 IU recommendation for darker-skinned individuals for years. The guidance has still not changed.
For Black British adults in their 40s and 50s, the age range where years of low vitamin D begin to compound their effects, this is not an academic debate. It is a real and ongoing health disadvantage.
What the Clinical Trials Say About Dosing
The clinical trial evidence on what actually works for adults of African descent is consistent:
- One trial of 328 African American adults found that roughly 1,640 IU per day was needed to get nearly all participants above the minimum adequate threshold, and 4,000 IU per day was needed for the majority to reach an optimal level. The standard 400 IU UK recommendation achieved neither.
- A one-year trial in Black and White men found that 4,000 IU per day completely eliminated the vitamin D level gap between the two groups, with no significant safety concerns.
- A study specifically examining children with the GC1F/GC1F genotype found that 75% did not reach vitamin D sufficiency even when meeting the current recommended daily allowance, compared with children with other variants, who did. This directly shows that the GC1F gene variant changes how much vitamin D you need.
A Practical Protocol Based on the Evidence
If you are of African descent and living in the UK, here is what the evidence supports:
1. Get your vitamin D tested. Ask your GP for a 25-OHD blood test. The target is above 75 nmol/L for optimal function — not just above 50 nmol/L, which is the conventional adequacy threshold.
2. Supplement at a meaningful dose. The clinical evidence supports 2,000 to 4,000 IU per day for adults of African descent to achieve and maintain adequate vitamin D levels. The standard 400-800 IU dose is likely insufficient. Doses above 4,000 IU should be discussed with a healthcare professional.
3. Choose vitamin D3, not D2. D3 (cholecalciferol) raises blood levels more effectively than D2 and is the form your body naturally produces from sunlight.
4. Take it alongside the right supporting nutrients. Vitamin D works as part of a network. Vitamin K2 directs calcium to bones rather than arteries. Magnesium is essential for converting vitamin D into its active form. Zinc supports how your cells respond to vitamin D. Taking vitamin D alone, without these co-nutrients, is less effective.
5. Retest after 12 weeks. Check your levels again after 3 months on a corrective dose to confirm they are within an adequate range. Adjust if needed.
The Bigger Picture
Understanding the GC1F gene is not just personally useful. It is a window into how health research and public health guidelines, built predominantly on studies of European populations, can systematically fail communities with different genetic backgrounds.
The science on GC1F does not suggest any biological disadvantage. If anything, it suggests the opposite: a potentially superior immune system, a meaningful reduction in cancer risk, and a protein architecture that may offer real protection. But that advantage exists alongside a public health gap that has never been properly closed.
Knowing your own biology is not a luxury. It is a health essential. And that is exactly what Morlongevity exists to help you act on.
Your Next Step
Our free guide, The Black Professional’s Vitamin D Action Plan, translates the research covered in this article into a practical, step-by-step protocol — including what to test, how to interpret your results, realistic dosing targets from clinical trials, co-nutrients to combine, and how to discuss personalised supplementation with your GP or pharmacist.
[Download the Vitamin D Action Plan → link]Â
Dele Abudu is a GPhC-registered pharmacist and founder of Morlongevity. The information in this article is for educational purposes and does not constitute medical advice. Individual circumstances vary; please consult a qualified healthcare professional before changing your supplementation protocol.
